Source comparison
Mechanism of Action: Upstream Pituitary Signaling vs Direct Receptor Activation
CJC-1295 functions as a growth hormone-releasing hormone (GHRH) analog with a drug affinity complex (DAC) modification that extends its plasma half-life to approximately 6–8 days compared to native GHRH's sub-10-minute duration. The peptide binds to GHRH recep
This comparison does not assign a generated winner or score.
- CJC-1295 functions as a growth hormone-releasing hormone (GHRH) analog with a drug affinity complex (DAC) modification that extends its plasma half-life to approximately 6–8 days compared to native GHRH's sub-10-minute duration. The peptide binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, triggering cyclic AMP (cAMP) accumulation and subsequent GH secretion. This mechanism preserves the body's endogenous pulsatile GH release pattern. The same circadian rhythm that produces peak secretion during deep sleep and follows ultradian cycles throughout the day. Because CJC-1295 works through the hypothalamic-pituitary axis, it maintains negative feedback regulation via somatostatin, preventing uncontrolled GH elevation.
- IGF-1 LR3 operates through an entirely different pathway. The peptide is a recombinant analog of insulin-like growth factor 1 (IGF-1) with two structural modifications: an arginine substitution at the third position (R3) and a 13-amino-acid N-terminal extension. These changes dramatically reduce IGF-1 LR3's affinity for IGF-binding proteins (IGFBPs), particularly IGFBP-3, which normally sequesters more than 95% of circulating IGF-1 and limits its bioavailability. Unbound IGF-1 LR3 circulates freely for 20–30 hours. Approximately 2,000–3,000 times longer than native IGF-1's 10-minute half-life. And binds directly to IGF-1 receptors (IGF-1R) on muscle, bone, and adipose tissue. Receptor activation triggers the PI3K/Akt/mTOR pathway, stimulating protein synthesis, glucose uptake, and cellular proliferation without requiring upstream GH secretion.
- The practical distinction for research design: CJC-1295 amplifies systemic GH and its downstream mediators (including endogenous IGF-1 production in the liver), making it suitable for studies examining the full GH/IGF-1 axis and its metabolic effects on body composition, lipolysis, and insulin sensitivity. IGF-1 LR3 isolates IGF receptor signaling, bypassing GH entirely. Ideal for tissue-specific anabolic research where direct receptor activation is the independent variable. At Real Peptides, we manufacture both peptides with exact amino-acid sequencing to guarantee purity and consistency in research applications where mechanism specificity determines model validity.